NASDAQ
TARA

Protara Therapeutics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Protara Therapeutics Inc Stock Price

Vitals

Today's Low:
$2.12
Today's High:
$2.2
Open Price:
$2.18
52W Low:
$2.1
52W High:
$4.429
Prev. Close:
$2.12
Volume:
6293

Company Statistics

Market Cap.:
$24.70 million
Book Value:
7.537
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
-19.92%
Return on Equity TTM:
-58.09%

Company Profile

Protara Therapeutics Inc had its IPO on 2014-10-22 under the ticker symbol TARA.

The company operates in the Healthcare sector and Biotechnology industry. Protara Therapeutics Inc has a staff strength of 25 employees.

Stock update

Shares of Protara Therapeutics Inc opened at $2.18 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.12 - $2.2, and closed at $2.12.

This is a 0% increase from the previous day's closing price.

A total volume of 6,293 shares were traded at the close of the day’s session.

In the last one week, shares of Protara Therapeutics Inc have slipped by -2.75%.

Protara Therapeutics Inc's Key Ratios

Protara Therapeutics Inc has a market cap of $24.70 million, indicating a price to book ratio of 0.2413 and a price to sales ratio of 0.

In the last 12-months Protara Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-39544000. The EBITDA ratio measures Protara Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Protara Therapeutics Inc’s operating margin was 0% while its return on assets stood at -19.92% with a return of equity of -58.09%.

In Q2, Protara Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Protara Therapeutics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-5.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Protara Therapeutics Inc’s profitability.

Protara Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 1.5954. Its price to sales ratio in the trailing 12-months stood at 0.

Protara Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$95.14 million
Total Liabilities
$4.93 million
Operating Cash Flow
$0
Capital Expenditure
$2000
Dividend Payout Ratio
0%

Protara Therapeutics Inc ended 2024 with $95.14 million in total assets and $0 in total liabilities. Its intangible assets were valued at $95.14 million while shareholder equity stood at $85.23 million.

Protara Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $4.93 million in other current liabilities, 11000.00 in common stock, $-180303000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.98 million and cash and short-term investments were $80.36 million. The company’s total short-term debt was $949,000 while long-term debt stood at $0.

Protara Therapeutics Inc’s total current assets stands at $84.27 million while long-term investments were $0.00 and short-term investments were $46.38 million. Its net receivables were $344000.00 compared to accounts payable of $1.85 million and inventory worth $3.56 million.

In 2024, Protara Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $2000.

Comparatively, Protara Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$2.12
52-Week High
$4.429
52-Week Low
$2.1
Analyst Target Price
$31.4

Protara Therapeutics Inc stock is currently trading at $2.12 per share. It touched a 52-week high of $4.429 and a 52-week low of $4.429. Analysts tracking the stock have a 12-month average target price of $31.4.

Its 50-day moving average was $2.42 and 200-day moving average was $2.96 The short ratio stood at 1.3 indicating a short percent outstanding of 0%.

Around 1598.9% of the company’s stock are held by insiders while 5177.5% are held by institutions.

Frequently Asked Questions About Protara Therapeutics Inc

The stock symbol (also called stock or share ticker) of Protara Therapeutics Inc is TARA

The IPO of Protara Therapeutics Inc took place on 2014-10-22

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$399.7
-21
-4.99%
Pharvaris BV (PHVS)
$19.85
0.25
+1.28%
Proterra Inc (PTRA)
$0
0
0%
$227.55
-5.55
-2.38%
$88.1
-1.8
-2%
BERYL DRUGS LTD. (BERLDRG)
$21.72
-0.43
-1.94%
$331.77
-6.17
-1.83%
$1444.4
-25.95
-1.76%
$12.38
-0.49
-3.81%
$51.23
-1.66
-3.14%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. The company is headquartered in New York, New York.

Address

345 Park Avenue South, New York, NY, United States, 10010